Increased tissue damage and lesion volumes in African Americans with multiple sclerosis

Neurology

Volumn 74, Issue 7, 2010, Pages 538-544

  Weinstock Guttman, B ^a   Ramanathan, M ^a,c   Hashmi, K ^b   Abdelrahman, N ^b   Hojnacki, D ^a   Dwyer, M G ^b   Hussein, S ^b   Bergsland, N ^b   Munschauer, F E ^a   Zivadinov, R ^a,b  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; MITOXANTRONE;

ADULT; AFRICAN AMERICAN; ARTICLE; BRAIN ATROPHY; BRAIN DAMAGE; CONTROLLED STUDY; DISABILITY; DISEASE DURATION; EUROPEAN AMERICAN; FEMALE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT DURATION; WHITE MATTER;

EID: 77149137080     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181cff6fb     Document Type: Article

References (32)

1. Alter M. Multiple sclerosis in the Negro. Arch Neurol 1962;7:83-91.
2. Kurtzke JF, Beebe GW, Norman JE, Jr. Epidemiology of multiple sclerosis in U.S. veterans: 1: race, sex, and geographic distribution. Neurology 1979;29:1228-1235.
3. Kurtzke JF, Delasnerie-Laupretre N, Wallin MT. Multiple sclerosis in North African migrants to France. Acta Neurol Scand 1998;98:302-309.
4. Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, et al. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler 2003;9:293-298.
5. Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004;63:2039-2045. (Pubitemid 39636249)
6. Morariu MA, Linden M. Multiple sclerosis in American blacks. Acta Neurol Scand 1980;62:180-187.
7. Dean G, Elian M. Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;63: 565-568.
8. Cabre P, Signate A, Olindo S, et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 2005;128:2899-2910.
9. Kaufman MD, Johnson SK, Moyer D, Bivens J, Norton HJ. Multiple sclerosis: severity and progression rate in African Americans compared with whites. Am J Phys Med Rehabil 2003;82:582-590.
10. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology 2006;66:1235-1240.
11. Naismith RT, Trinkaus K, Cross AH. Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler 2006;12:775-781.
12. Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol 1998;55:186-192.
13. Debouverie M, Lebrun C, Jeannin S, Pittion-Vouyovitch S, Roederer T, Vespignani H. More severe disability of North Africans vs Europeans with multiple sclerosis in France. Neurology 2007;68:29-32.
14. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71: 136-144.
15. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey: National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
16. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-1247.
17. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage 2000;11:805-821.
18. Carone DA, Benedict RH, Dwyer MG, et al. Semiautomatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. Neuroimage 2006;29:505-514.
19. Zivadinov R, Weinstock-Guttman B, Benedict R, et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet 2007;16:2659-2668.
20. Benedict RH, Bruce JM, Dwyer MG, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006;63:1301-1306.
21. Deloire-Grassin MS, Brochet B, Quesson B, et al. In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J Neurol Sci 2000;178:10-16.
22. Dousset V, Degreze P, Mieze S, Sesay M, Basse-Cathalinat B, Caille JM. Magnetization transfer on in vitro circulating blood: implications for time-of-flight MR angiography. J Magn Reson Imaging 1995;5:786-788.
23. Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003;60:1073-1081.
24. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004; 56:407-415.
25. Caillier SJ, Briggs F, Cree BA, et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol 2008;181:5473-5480.
26. Oksenberg JR, Barcellos LF, Cree BA, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004;74:160-167.
27. Cree BA, Reich DE, Khan O, et al. Modification of multiple sclerosis phenotypes by African ancestry at HLA. Arch Neurol 2009;66:226-233.
28. Huang R, Hughes M, Mobley S, Lanham I, Poduslo SE. APOE genotypes in African American female multiple sclerosis patients. Neurosci Lett 2007;414:51-56.
29. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis: part II: noninfectious factors. Ann Neu-rol 2007;61:504-513. (Pubitemid 47068132)
30. Pederson LL, Ahluwalia JS, Harris KJ, McGrady GA. Smoking cessation among African Americans: what we know and do not know about interventions and self-quitting. Prev Med 2000;31:23-38.
31. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinsh-enker BG. The clinical course of neuromyelitis optica (De-vic's syndrome). Neurology 1999;53:1107-1114.
32. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.